Leo Pharma owner: "You can’t go public without a growth outlook or an interesting pipeline"
Leo Pharma must create growth and secure a proper pipeline. ”The rest can be figured out if those two things are sorted,” says Peter Haahr, CEO of Leo Pharma’s majority shareholder, the Leo Foundation.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
Several top managers have been replaced and the organization’s management looks markedly different from just a few years ago. The company is leaking money, and has announced that 1,000 positions are to be terminated.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Layoffs and restructuring will prepare Leo Pharma for IPO
For subscribers
Leo Pharma poaches Novo Nordisk VP to lead US division
For subscribers
.jpg)
.jpg&w=384&q=75)
